Company / Working Capital
Zenas BioPharma, Inc. Working Capital History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$288.5M
FY2025
5-year range
$36.5M / $298.6M
FY2023-FY2025
Trend
-3.4%
vs FY2024
Sector context
#145 of 213
Health Care
What the data says
At $289M, Zenas BioPharma, Inc.'s working capital ranks #145 of 213 in the Health Care sector. Improved from $37M to $289M over the past 2 years.
Based on SEC 10-K filings.
$289M in FY2025.
Improved from $37M to $289M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#145 of 213 in Health CareTop 68% of 213This company $288.5M Sector average $934.6M
▼
-69.1% below sector average
Key checks
Key Insights
- In FY2025, working capital decreased 3.4% year-over-year.
- Ranks #145 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $288.5M | -3.4% |
| FY2024 | $298.6M | +717.1% |
| FY2023 | $36.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026